Clinical Trial

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Study acronym: emnergize
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize
Protocol Amendment History 4 changes
notable Trial sites expanded: 61 -> 71 locations 2026-07-23
notable Trial sites expanded: 56 -> 61 locations 2026-06-13
notable Trial sites expanded: 43 -> 56 locations 2026-05-29
notable Trial sites expanded: 19 -> 43 locations 2026-05-09
Trial Details
NCT Number NCT07091630
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Enrollment 160 participants
Start Date 2025-09-16
Primary Completion 2027-10-07 (estimated)
Study Completion 2031-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-22